NO20052009L - Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom - Google Patents
Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndromInfo
- Publication number
- NO20052009L NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- myelodysplastic syndrome
- acute leukemia
- combination therapy
- pharmaceutical combinations
- Prior art date
Links
- 206010000830 Acute leukaemia Diseases 0.000 title abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 abstract 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
- E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
- E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
- E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/035532 WO2004043461A1 (en) | 2002-11-06 | 2002-11-06 | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052009D0 NO20052009D0 (no) | 2005-04-25 |
| NO20052009L true NO20052009L (no) | 2005-06-27 |
Family
ID=32311637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052009A NO20052009L (no) | 2002-11-06 | 2005-04-25 | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1575582A4 (de) |
| JP (1) | JP2006508119A (de) |
| CN (1) | CN1720044A (de) |
| AU (2) | AU2002348178A1 (de) |
| BR (1) | BR0215935A (de) |
| CA (1) | CA2504611A1 (de) |
| CR (1) | CR7804A (de) |
| MX (1) | MXPA05004711A (de) |
| NO (1) | NO20052009L (de) |
| WO (1) | WO2004043461A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977320B2 (en) | 2004-10-29 | 2011-07-12 | The Regents Of The University Of California | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |
| EP1661584A1 (de) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen |
| KR20080030659A (ko) * | 2005-07-06 | 2008-04-04 | 카니사 파마슈티컬즈, 인크. | 칼리키아미신-항체 컨쥬게이트를 조스퀴다르와 조합하여사용하는 암 환자의 치료 |
| ATE521366T1 (de) * | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| CN1994293A (zh) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | 冬凌草甲素在制药中的应用 |
| AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| AU2008216083B2 (en) * | 2007-02-16 | 2014-02-06 | Jazz Pharmaceuticals Therapeutics, Inc. | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| EP2249831A2 (de) | 2007-12-10 | 2010-11-17 | Sunesis Pharmaceuticals, Inc. | Verfahren zur verwendung von (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carbonsäure zur behandlung von vorangehenden hämatologischen erkrankungen |
| WO2010024374A1 (ja) | 2008-08-29 | 2010-03-04 | 学校法人北里研究所 | Ｄｎａメチル化阻害剤の薬剤効果検出方法 |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
| US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
| EP3469001A4 (de) | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | Kombinationen von pbd-basierten antikörper-arzneimittel-konjugaten mit flt3-inhibitoren |
| ES2971466T3 (es) * | 2017-06-22 | 2024-06-05 | Servier Lab | Combinación de un inhibidor de Mcl-1 y un tratamiento estándar de atención para cánceres hematológicos, usos y composiciones farmacéuticas de la misma |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| CN113631193A (zh) * | 2019-01-28 | 2021-11-09 | 德州大学系统董事会 | 用于治疗癌症的金属螯合剂组合疗法 |
| CN110123825B (zh) * | 2019-05-28 | 2021-11-30 | 宁波市鄞州人民医院 | 一种包含去甲氧柔红霉素的药物组合物 |
| EP4236970A1 (de) * | 2020-10-27 | 2023-09-06 | Vor Biopharma Inc. | Zusammensetzungen und verfahren zur behandlung hämatopoetischer malignitäten |
| WO2025214401A1 (zh) * | 2024-04-12 | 2025-10-16 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物、组合物及其用途和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| DE60140063D1 (de) * | 2000-08-08 | 2009-11-12 | Immunomedics Inc | Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper |
-
2002
- 2002-11-06 WO PCT/US2002/035532 patent/WO2004043461A1/en not_active Ceased
- 2002-11-06 BR BR0215935-0A patent/BR0215935A/pt not_active IP Right Cessation
- 2002-11-06 MX MXPA05004711A patent/MXPA05004711A/es active IP Right Grant
- 2002-11-06 CA CA002504611A patent/CA2504611A1/en not_active Abandoned
- 2002-11-06 JP JP2004551359A patent/JP2006508119A/ja active Pending
- 2002-11-06 AU AU2002348178A patent/AU2002348178A1/en not_active Abandoned
- 2002-11-06 EP EP02784400A patent/EP1575582A4/de not_active Withdrawn
- 2002-11-06 CN CNA028301404A patent/CN1720044A/zh active Pending
-
2005
- 2005-04-25 NO NO20052009A patent/NO20052009L/no not_active Application Discontinuation
- 2005-04-25 CR CR7804A patent/CR7804A/es not_active Application Discontinuation
-
2010
- 2010-03-22 AU AU2010201113A patent/AU2010201113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1575582A4 (de) | 2009-03-11 |
| EP1575582A1 (de) | 2005-09-21 |
| AU2002348178A1 (en) | 2004-06-03 |
| BR0215935A (pt) | 2005-08-09 |
| NO20052009D0 (no) | 2005-04-25 |
| CR7804A (es) | 2008-10-29 |
| CN1720044A (zh) | 2006-01-11 |
| WO2004043461A1 (en) | 2004-05-27 |
| JP2006508119A (ja) | 2006-03-09 |
| AU2010201113A1 (en) | 2010-04-15 |
| MXPA05004711A (es) | 2005-08-03 |
| CA2504611A1 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007022073A3 (en) | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives | |
| EP4424372A3 (de) | Verbindungen und verfahren zur behandlung von virusinfektionen | |
| NZ543867A (en) | Modified fluorinated nucleoside analogues | |
| BR0215935A (pt) | Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica | |
| CY1113012T1 (el) | Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης | |
| AP2005003211A0 (en) | 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections. | |
| ES2138969T3 (es) | Combinacion de nucleosidos antivirales. | |
| DK1644392T3 (da) | Kulhydratderivater af rapamycin | |
| BRPI9809791B8 (pt) | compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos | |
| DK0526537T3 (da) | 5-Benzylbarbituratderivater | |
| WO2003099346A3 (en) | Compositions and methods for coating medical implants | |
| DK1412368T3 (da) | Sukkerderivater af hydromorfon, dihydromorfin, dihydroisomorfin, sammensætninger deraf og anvendelser til behandling eller forebyggelse af smerter | |
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
| BRPI0503981A (pt) | substituto do açúcar apetecìvel, de baixa caloria com agente de volume insolúvel em água | |
| WO2004028475A3 (en) | Glycosylceramide analogues | |
| PT1368041E (pt) | Composicao aquosa de anfotericina | |
| BR9908391A (pt) | Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina | |
| DK1216256T3 (da) | Makrolid-antibiotika og behandling af pasteurellosis | |
| WO2008104893A3 (en) | Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof | |
| DK1079840T3 (da) | Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer | |
| UA83204C2 (ru) | Комбинированная терапия для лечения острого лейкоза и миелодиспластичного синдрома | |
| BRPI0518700A2 (pt) | combinaÇÕes antitumorais, contendo um agente inibidor de vegf e 5fu ou um de seus derivados | |
| EP4464701A4 (de) | 1,3-benzodioxolderivatverbindung und pharmazeutische zusammensetzung damit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |